Could a cancer drug put nerve disease into Long-Term remission?
NCT ID NCT04480450
Summary
This study aimed to test if rituximab, a drug that targets immune B cells, could help control Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a disorder where the immune system attacks the nerves. Researchers wanted to see if the drug could allow some patients to stop their current medications and achieve long-term remission. The trial was designed for adults with stable CIDP who were already being treated with other therapies, but the study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.